Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target messenger RNAs (mRNAs) of diacylglycerol kinase zeta (DGKζ) small interfering RNA (siRNA) refer to the collection of transcripts unintentionally regulated by the siRNA guide strand. While the intended therapeutic target is DGKζ—an enzyme that modulates T-cell signaling by converting diacylglycerol to phosphatidic acid—the siRNA can also bind to other mRNAs with partial sequence complementarity (Cancer Research, 2016, 76(8):2128-2140). This binding typically occurs in the 3' untranslated region (UTR) and is driven by the "seed" region of the siRNA, mimicking the natural regulatory mechanism of microRNAs (Nature, 2007, 445:545–548). Such off-target effects can lead to the unintended downregulation of numerous genes, potentially causing cellular toxicity or confounding the interpretation of therapeutic efficacy. In drug development, these unintended interactions represent a significant safety concern and a challenge for ensuring the specificity of RNAi-based therapies. Strategies to minimize these effects include chemical modifications of the siRNA and bioinformatic filtering to avoid sequences with high seed-match frequency in the human transcriptome (Nature Biotechnology, 2003, 21:635–637).
MicroRNA-like silencing via seed-region complementarity (nucleotides 2-8) to the 3' untranslated region (UTR) of non-target mRNAs, leading to translational repression or mRNA degradation (Nature Biotechnology, 2003, 21:635–637).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNAs of diacylglycerol kinase zeta small interfering RNA (DGKζ siRNA off-targets).